Eze/Simva Switch Study in Diabetics (0653A-807)

A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.

A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.

Inclusion Criteria:

• Currently being treated with Atorvastatin 10 mg for at least 6 weeks
• Have Type 2 Diabetes
• Weight must be stable for more than 6 weeks before entering the study

Exclusion Criteria:

• Consume more than 14 alcoholic drinks per week.
• Pregnant or lactating
• Have taken another investigation drug within 3 months of starting this study
• History of congestive heart failure, heart attack, coronary artery bypass surgery
• Uncontrolled high blood pressure
• HIV positive
• History of cancer in the last 5 years